Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.
Neuromyopathy is a rare side effect of chronic colchicine therapy, most often occurring in patients with chronic renal failure. Drugs interacting with colchicine metabolism through CYP(3)A(4) and P-glycoprotein can accelerate accumulation and toxicity. We describe a case of an interaction between clarithromycin and colchicine resulting in acute neuromyopathy, and we conclude that combined use of macrolides and colchicine should be avoided.
van der Velden
W
W
Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Huussen
J
J
Ter Laak
H
H
de Sévaux
R
R
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000009:adverse effects; D017291:Clarithromycin / Q000009:adverse effects*; D003078:Colchicine / Q000009:adverse effects*; D051544:Cytochrome P-450 CYP3A; D004347:Drug Interactions; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D008297:Male; D009468:Neuromuscular Diseases / Q000139:chemically induced*; D012307:Risk Factors; D019821:Simvastatin / Q000009:adverse effects; D050257:Tubulin Modulators / Q000009:adverse effects*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000900:Anti-Bacterial Agents; D000924:Anticholesteremic Agents; D050257:Tubulin Modulators; D019821:Simvastatin; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D017291:Clarithromycin; D003078:Colchicine